Formulation of Extended-Release Gliclazide Tablet Using a Mathematical Model for Estimation of Hypromellose
Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 32870
Formulation of Extended-Release Gliclazide Tablet Using a Mathematical Model for Estimation of Hypromellose

Authors: Farzad Khajavi, Farzaneh Jalilfar, Faranak Jafari, Leila Shokrani


Formulation of gliclazide in the form of extended-release tablet in 30 and 60 mg dosage forms was performed using hypromellose (HPMC K4M) as a retarding agent. Drug-release profiles were investigated in comparison with references Diamicron MR 30 and 60 mg tablets. The effect of size of powder particles, the amount of hypromellose in formulation, hardness of tablets, and also the effect of halving the tablets were investigated on drug release profile. A mathematical model which describes hypromellose behavior in initial times of drug release was proposed for the estimation of hypromellose content in modified-release gliclazide 60 mg tablet. This model is based on erosion of hypromellose in dissolution media. The model is applicable to describe release profiles of insoluble drugs. Therefore, by using dissolved amount of drug in initial times of dissolution and the model, the amount of hypromellose in formulation can be predictable. The model was used to predict the HPMC K4M content in modified-release gliclazide 30 mg and extended-release quetiapine 200 mg tablets.

Keywords: Hypromellose, gliclazide, drug release, modified-release tablet, mathematical model.

Digital Object Identifier (DOI):

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 2267


[1] Kadri B. V.; Mechanism of drug release from matrix tablets involving moving boundaries, Master of Science thesis, Department of Pharmaceutical Sciences, University of Toronto, 2001.
[2] Piriyaprasarth, S.; Sriamornsak, P.; Effect of source variation on drug release from HPMC tablets: Linear regression modeling for prediction of drug release. International Journal of Pharmaceutics 2011; 411: 36-42.
[3] Shah AC, Britten NJ, Olanoff LS and Basalamenti NJ: Gel-matrix systems exhibiting bimodal controlled release of oral drug delivery. Journal of Control Release 1989; 9: 169-174.
[4] Tahara K, Mikawa M, Yokohoma S and Nishihata T: Characteristics of intestinal absorption of adinazolam and in vivo evaluation of oral sustained release tablets of adinazolam in beagle dogs. International Journal of Pharmaceutics 1993; 99:311-320.
[5] Skoug JW, Borin MT, Fleishaker JC and Cooper AM: In vitro and In vivo evaluation of whole and half tablets of sustained release adinazolammesylate. Pharmaceutical Research 1991; 8:1482-1488.
[6] Brazel CS and Peppas NA: Modeling of drug release from swellable polymers. European Journal of Pharmaceutics and Biopharmaceutics 2000; 49:47-58.
[7] Tahara K, Yamamoto K and Nishihata T: Overall mechanism behind matrix sustained release (SR) tablets prepared with hydroxypropyl methylcellulose 2910. Journal of Control Release 1995; 35:59-66.
[8] Kim H and Fassihi R: Application of binary polyrner system in drug release rate modulation 2. Influence of formulation variables and hydrodynamic conditions on release kinetics. Journal of Pharmaceutical Sciences 1997; 86:323-328.
[9] Raju PN, Prakash K, Rao TR, Reddy BCS, Sreenivasulu V and Narasu ML: Effect of tablet surface area and surface area/volume on drug release from Lamivudine extended release matrix tablets. International Journal of Pharmaceutical Sciences and Nanotechnology 2010; 3:872-876.
[10] Afkhami A and Khajavi F: A diffusion-kinetic model for optical sensors to predict heterogeneous rate constants, diffusion coefficients and Stokes radii of ions with the aid of chemometric methods. Sensors and Actuators B: Chemical 2010; 173:620-629.
[11] Crank J: The Mathematics of Diffusion. Oxford University Press; London, 1975.